country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-N21657

Copy Link Print Information

Procumbenoside I

Procumbenoside I is a naturally derived broad-spectrum antiviral agent targeting the SFTSV glycoprotein Gn. Procumbenoside I binds to the conserved B domain of SFTSV Gn, blocking the binding and internalization steps during viral entry. Procumbenoside I inhibits the entry of VSV, H5N1, and SARS-CoV-2 pseudoviral particles, while exhibiting antiviral activity against bunyaviruses such as LCMV and WELV. Procumbenoside I protects mice against lethal SFTSV challenge, reducing mortality and alleviating pathological damage. Procumbenoside I is useful for research related to viral infections.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

CAS No.: 2243471-10-3
화학식: C₂₆H₂₄O₁₂
분자량:528.47

보관:

Please store the product under the recommended conditions in the Certificate of Analysis.

Procumbenoside I Chemical Structure

CAS No.: 2243471-10-3

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
순도&문서
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

Cellular Effect

Cell Line	Type	Value	Description	References
Huh-7	IC50	0.583 μM	Inhibition of SFTSV infection in human Huh7 cells assessed by reduction in viral load in cell culture supernatants quantified by qRT-PCR at 48 h post-infection. Inhibition of SFTSV infection in human Huh7 cells assessed by reduction in viral load in cell culture supernatants quantified by qRT-PCR at 48 h post-infection.	42425227
A549	EC50	0.014 μM	Antiviral activity against VSVpp in A549 human lung epithelial cells assessed by inhibition of pseudovirus infection. Antiviral activity against VSVpp in A549 human lung epithelial cells assessed by inhibition of pseudovirus infection.	33818100
A549	EC50	0.0063 μM	Antiviral activity against H5N1pp in A549 human lung epithelial cells assessed by inhibition of pseudovirus infection. Antiviral activity against H5N1pp in A549 human lung epithelial cells assessed by inhibition of pseudovirus infection.	33818100
A549	CC₅₀	1.13 μM	Cytotoxicity against A549 human lung epithelial cells. Cytotoxicity against A549 human lung epithelial cells.	33818100
HEK-293T	EC50	1.13 μM	Antiviral activity against SARS-CoV-2pp in HEK-293T-hACE2 cells assessed by luciferase assay after 72 hrs infection. Antiviral activity against SARS-CoV-2pp in HEK-293T-hACE2 cells assessed by luciferase assay after 72 hrs infection.	33818100
HEK-293T	CC₅₀	2.15 μM	Cytotoxicity against HEK-293T-hACE2 cells. Cytotoxicity against HEK-293T-hACE2 cells.	33818100

In Vitro

Viral InfectionOthers

Viral Infection

Procumbenoside I (2.5-10 μM; 48 h) effectively inhibits SFTSV infection in Huh7 cells with an IC₅₀ of 0.583 μM and a CC₅₀ of >20 μM^[1].
Procumbenoside I does not exert a direct virucidal effect on SFTSV particles^[1].
Procumbenoside I (10 μM; 1 h before infection, 2 h infection, 24 h collection) inhibits SFTSV infection at the viral entry stage, with maximal effect when present before and during infection^[1].
Procumbenoside I (5-20 μM; 1 h pretreatment, 15 min cooling, 2 h binding) inhibits the binding of SFTSV to Huh7 cells and the entry of SFTSV into Huh7 cells^[1].
Procumbenoside I (compound 5) (25 μM) exhibits potent antiviral activity against VSVpp and H5N1pp in A549 cells, with EC₅₀ values of 0.014 μM and 0.0063 μM, respectively^[2].
Procumbenoside I (72 h) exhibits moderate antiviral activity against SARS-CoV-2pp in HEK-293T-hACE2 cells with an EC₅₀ of 1.13 μM^[2]^[3].

Others

Procumbenoside I (100 μM; 1 h incubation, 5 min heating) directly interacts with and stabilizes SFTSV Gn but not Gc in Huh7 cell lysates^[1].
Procumbenoside I (5-400 μM; 1 h incubation, 5 min heating) stabilizes SFTSV Gn in a dose-dependent manner^[1].
Procumbenoside I (100 μM; 1 h incubation, 20 min pronase treatment) binds to SFTSV Gn, thereby protecting it from pronase-mediated degradation^[1].
Procumbenoside I directly binds to SFTSV-Gn with a K_D of 5.73 × 10^-5 M^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

Huh7 cells
Concentration:

2.5, 10 μM
Incubation Time:

48 h
Result:

Inhibited SFTSV infection with an IC₅₀ of 0.583 μM.
Exhibited a CC₅₀ of >20 μM.
Yielded a selection index (SI) of >34.

Real Time qPCR^[1]

Cell Line:

Huh7 cells
Concentration:

10 μM
Incubation Time:

1 h (pre-infection); 2 h (infection); 24 h (collection)
Result:

Reduced vRNA levels when present prior to and during infection.
Showed a more limited inhibitory effect upon post-infection addition.

Real Time qPCR^[1]

Cell Line:

Huh7 cells
Concentration:

5, 10, 20 μM
Incubation Time:

1 h (pre-treatment); 15 min (chilling); 2 h (binding)
Result:

Reduced vRNA levels compared to the control group.
Reduced intracellular vRNA levels compared to the control group.

Western Blot Analysis^[1]

Cell Line:

Huh7 cell lysates
Concentration:

5, 25, 50, 100, 200, 400 μM
Incubation Time:

1 h (incubation); 5 min (heating)
Result:

Stabilized Gn in a dose-dependent manner.

Western Blot Analysis^[1]

Cell Line:

Huh7 cell lysates
Concentration:

100 μM
Incubation Time:

1 h (incubation); 20 min (pronase treatment)
Result:

Reduced pronase-mediated degradation of SFTSV Gn.

In Vivo

Bacterial Infection

Procumbenoside I (1-5 mg/kg/day; intraperitoneal injection; daily; for 5 consecutive days) confers potent protection against lethal SFTSV infection in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6J (male, six-week-old, pretreated with anti-IFNAR1 blocking antibody and challenged intraperitoneally with SFTSV, infected with 100 μL of SFTSV solution (1.5 × 10⁵ PFU/mL))^[1]
Dosage:

1, 5 mg/kg/day
Administration:

i.p.; daily; 5 consecutive days
Result:

Reduced fatality rates with survival rates of 66.7% at 1 mg/kg/day and 83.3% at 5 mg/kg/day.
Significantly reduced serum viral loads and splenic viral titers at both doses.
Confirmed inhibitory effect on viral infection by immunohistochemical analysis of spleen sections using anti-SFTSV NP antibody.
Alleviated splenic pathological damage such as attenuating the loss of white pulp by H&E staining.

Related Protocols :

Research Protocol for Infectious Diseases

Chemical Information

CAS No. 2243471-10-3
분자량 528.47
화학식 C₂₆H₂₄O₁₂
SMILES

O=C1C2=C(C=3C(C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)=C2CO1)=CC(OC)=C(O)C3)C=5C=C6C(=CC5)OCO6
Structure Classification
- Phenylpropanoids
- Lignans
Initial Source
선적

Room temperature in continental US; may vary elsewhere.
보관

Please store the product under the recommended conditions in the Certificate of Analysis.

순도&문서

Handling Instructions (2659 KB)

References

[1]. Huang J, et al. Effectiveness of lignans against severe fever with thrombocytopenia syndrome virus infection. Virologica Sinica. 2026 Aug;41(4):912-922.

[2]. Zhao Y, et al. Axial Chirality and Antiviral Activity Evaluation of Arylnaphthalene Lignan Glycosides from Justicia procumbens. Asian Journal of Organic Chemistry, 2022.

[3]. Zhao Y. Axial chirality and antiviral activity evaluation of arylnaphthalene lignan glycosides from Justicia procumbens. Asian Journal of Organic Chemistry. 2022 Aug;11(8):e202200267.

[4]. Guan L, et al. In-Depth Exploration of Chemical Constituents from Justicia procumbens L. Through UHPLC-Q-Exactive Orbitrap Mass Spectrometry. Molecules, 2025, 30: 3554.

Calculators

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

견적 받기 해외재고보유

Other size

견적 받기